Keytruda demonstrated a statistically significant and clinically meaningful improvement in event-free survival and major ...

The FDA granted priority review to pembrolizumab for neoadjuvant and adjuvant use in head and neck squamous cell carcinoma, ...

The FDA accepted a supplemental biologics license application for Opdivo plus Yervoy as a first-line treatment for some adult ...

The FDA accepted for priority review a supplemental Biologics License Application for Keytruda for resectable locally ...

Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the United States (U.S.) Food and Drug Administration (FDA) has accepted the Biologics License ...

Keytruda has been approved since 2016 as a second-line option after chemotherapy for patients with more advanced HNSCC that ...

Australian biotech Telix Pharmaceuticals (NASDAQ:TLX) announced late Tuesday that the U.S. Food and Drug Administration (FDA) has accepted its marketing application for TLX250-CDx and granted it ...

Insmed Incorporated (NASDAQ: INSM) announced on February 24, 2025 that the U.S. Food and Drug Administration (FDA) does not ...

The $149 Satechi 6-Port Charging Station can output 200W over multiple USB-C ports, although not as intelligently as the ...

Lynn Dekleva, who recently took a senior role at the agency, once led an aggressive effort by industry to block regulations ...

Education spokeswoman Sarah Henderson said a Coalition government would impose tougher caps on international and hold a zero ...

Reported EPS is $1.76, expectations were $1.17. John McCartney: Good morning, and welcome to Scotiabank’s 2025 First Quarter ...